TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.

Claire N Harrison et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.